(Q33471537)

27 July 2017

1 reference

title

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential (English)

1 reference

27 July 2017

Clissold SP

1

1 reference

PubMed ID

3286212

27 July 2017

Edwards C

series ordinal

2

1 reference

27 July 2017

1 March 1988

1 reference

27 July 2017

1 reference

27 July 2017

35

1 reference

27 July 2017

214-243

1 reference

27 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198835030-00003

27 July 2017

0 references

cites work

Effects of inhibitors of carbohydrate absorption or lipid metabolism on meal patterns of Zucker rats

1 reference

12 December 2020

alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus

1 reference

12 December 2020

Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor

1 reference

12 December 2020

Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose)

1 reference

12 December 2020

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man

1 reference

12 December 2020

Acarbose in reactive hypoglycemia: a double-blind study

1 reference

12 December 2020

Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption

1 reference

12 December 2020

Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor

1 reference

12 December 2020

Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal

1 reference

12 December 2020

Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.

1 reference

12 December 2020

Influence of an ??-amylase inhibitor (BAY d 7791) on blood glucose, serum insulin and nefa in starch loading tests in rats, dogs and man

1 reference

12 December 2020

Combined use of guar and acarbose in reduction of postprandial glycaemia

1 reference

12 December 2020

Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure

1 reference

12 December 2020

Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man

1 reference

12 December 2020

Effects of an α-Glucosidase Inhibitor, Acarbose, on Blood Glucose and Serum Lipids in Streptozotocin-Induced Diabetic Rats

1 reference

12 December 2020

Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor

1 reference

12 December 2020

Delay of Carbohydrate Absorption by Inhibitors of Intestinal ∝-Glucosidases

1 reference

12 December 2020

Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics

1 reference

12 December 2020

A glycoside-hydrolase inhibitor in treatment of dumping syndrome

1 reference

12 December 2020

alpha-Glucosidase inhibitors. New complex oligosaccharides of microbial origin

1 reference

12 December 2020

Low dose acarbose without symptoms of malabsorption in the dumping syndrome

1 reference

12 December 2020

Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421)

1 reference

12 December 2020

The physiology and pathophysiology of gastric emptying in humans

1 reference

12 December 2020

Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome

1 reference

12 December 2020

Effect of Acarbose on the production of hydrogen and methane and on hormonal parameters in young adults under standardized low-fibre mixed diets

1 reference

12 December 2020

Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics

1 reference

12 December 2020

Recent progress in the treatment of diabetes mellitus

1 reference

12 December 2020

Influence of acarbose on hyperglycemia induced by various carbohydrates in rats and oral starch tolerance in monkeys

1 reference

12 December 2020

A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition

1 reference

12 December 2020

Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.

1 reference

12 December 2020

Inhibition of human intestinalα-glucosidehydrolases by a new complex oligosaccharide

1 reference

12 December 2020

alpha-Glucosidase inhibition in obesity.

1 reference

12 December 2020

Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus

1 reference

12 December 2020

Effect of the?? glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics

1 reference

12 December 2020

Response of serum levels of gastric inhibitory polypeptide and insulin to sucrose ingestion during long-term application of acarbose

1 reference

12 December 2020

Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in Zucker (fafa) rats.

1 reference

12 December 2020

Blood glucose concentrations and glycosuria during and after one year of acarbose therapy

1 reference

12 December 2020

Scope and specificity of acarbose in slowing carbohydrate absorption in man

1 reference

12 December 2020

Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months

1 reference

12 December 2020

Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man

1 reference

12 December 2020

Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose

1 reference

12 December 2020

Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects

1 reference

12 December 2020

Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients

1 reference

12 December 2020

Modification of weight gain by an alpha-glucosidase inhibitor during refeeding in rats.

1 reference

12 December 2020

Inhibition of disaccharide digestion in rat intestine by the alpha-glucosidase inhibitor acarbose (BAY g 5421)

1 reference

12 December 2020

Effect of Acarbose on Blood Glucose Profile of Totally Insulin-Dependent Diabetic Patients

1 reference

12 December 2020

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

1 reference

12 December 2020

Effects of acarbose on food intake, body weight and fat depots in lean and obese rats.

1 reference

12 December 2020

Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor

1 reference

12 December 2020

Acarbose treatment of non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Effect of acarbose, pectin, a combination of acarbose with pectin, and placebo on postprandial reactive hypoglycaemia after gastric surgery

1 reference

12 December 2020

The Effects of an Alpha-Glucoside Hydrolase Inhibitor on Glycemia and the Absorption of Sucrose in Man Determined Using a Tracer Method

1 reference

12 December 2020

Long-term effect of acarbose on diurnal serum triglyceride, glucose, insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II diabetes.

1 reference

12 December 2020

Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia

1 reference

12 December 2020

10.2165/00003495-198835030-00003

Identifiers

DOI

1 reference

PubMed ID

3286212

Dimensions Publication ID

27 July 2017

0 references

1 reference

PubMed ID

3286212